Association of Metformin with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis

Simple item page
dc.contributor.authorParveen, Rizwanaen_US
dc.contributor.authorMishra, Pinkien_US
dc.contributor.authorLuthra, Revaen_US
dc.contributor.authorBajpai, Ramen_US
dc.contributor.authorAgarwal, Nidhien_US
dc.date.accessioned2023-07-21T11:28:16Z
dc.date.available2023-07-21T11:28:16Z
dc.date.issued2023-01
dc.description.abstractStudies have demonstrated high prevalence of mortality in coronavirus disease (COVID-19) patients with type 2 diabetes mellitus; however, the effects of antidiabetic pharmacotherapy on COVID-19 complications need further exploration. The aim of the study was to explore the association of metformin use and mortality in COVID-19 patients. A literature search was conducted using the databases Medline (via PubMed) and Cochrane Central Register of Controlled Trials until February 09, 2021. Nine studies were included in the meta-analysis, including 12,684 COVID-19 patients. The meta-analysis suggested 37% lower risk of mortality in patients receiving metformin (risk ratio: 0.63; 95% confidence interval: 0.50–0.78; p?<?0.001). However, no significant difference in hospitalization days between the two groups (p?=?0.197) was observed. The analysis revealed significantly lower risk of having obesity (p?<?0.001), hypertension (p?<?0.001), heart failure (p?<?0.001), and cerebrovascular disease (p?=?0.015) in the group receiving metformin. The analysis also demonstrated significantly lower risk of using anticoagulants (p?=?0.015), diuretics (p?<?0.001), and antiplatelets (p?=?0.010) in patients receiving metformin. Our findings suggest that metformin use decreases mortality in COVID-19 patients. However, randomized studies demonstrating the consequences of metformin use are needed to understand the magnitude of the beneficial effects of metforminen_US
dc.identifier.affiliationsCentre for Translational and Clinical Research, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, Indiaen_US
dc.identifier.affiliationsCentre for Translational and Clinical Research, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, Indiaen_US
dc.identifier.affiliationsCentre for Translational and Clinical Research, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, Indiaen_US
dc.identifier.affiliationsSchool of Medicine, Keele University, Staffordshire, United Kingdomen_US
dc.identifier.affiliationsCentre for Translational and Clinical Research, School of Chemical & Life Sciences, Jamia Hamdard, New Delhi, Indiaen_US
dc.identifier.citationParveen, Rizwanaen_US
dc.identifier.citationMishra, Pinkien_US
dc.identifier.citationLuthra, Revaen_US
dc.identifier.citationBajpai, Ramen_US
dc.identifier.citationAgarwal, Nidhi. Association of Metformin with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Annals of the National Academy of Medical Sciences. 2023 Jan; 59(1): 13-20en_US
dc.identifier.issn0379-038X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/220215
dc.languageenen_US
dc.publisherThieme Medical and Scientific Publishers Pvt. Ltden_US
dc.relation.issuenumber1en_US
dc.relation.volume59en_US
dc.source.urihttps://doi.org/10.1055/s-0042-1760353en_US
dc.subjectCOVID-19en_US
dc.subjecthospitalizationen_US
dc.subjectmetforminen_US
dc.subjectmortalityen_US
dc.subjectmeta-analysisen_US
dc.subjecttype 2 diabetesen_US
dc.subjectSARS-CoV-2en_US
dc.titleAssociation of Metformin with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ANAMS2023v59n1p13.pdf
Size:
1 MB
Format:
Adobe Portable Document Format
Download
Collections
Annals of the National Academy of Medical Sciences (India)